Respiration
Clinical Investigation
Malignant Pleural Effusion: Prognostic Factors for Survival and Response to Chemical Pleurodesis in a Series of 120 CasesMartínez-Moragón E.a · Aparicio J.b · Sanchis J.a · Menéndez R.a · Rogado M.C.a · Sanchis F.aDepartments of a Pneumology and b Medical Oncology, Hospital Universitario La Fe, Valencia, Spain
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: April 03, 1998
Issue release date: March – April
Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 4
ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)
For additional information: https://www.karger.com/RES
Abstract
Chemical pleurodesis is an effective treatment of malignant pleural effusions, but indications must be individualised to optimise its results. The aim of the present study was to investigate the relationship of various prognostic features with both the response rate to pleurodesis and the probability of patient survival. A non-concurrent cohort study was carried out in which 120 evaluable patients with malignant pleural effusion underwent pleurodesis. Lung (40%), breast (26.6%), and unknown primary site (12.5%) carcinomas were the most frequent neoplasms. Clinical data and pleural fluid parameters were analysed. Median overall survival was 9 months. Pleural fluid glucose (<60 mg/dl), Karnofsky performance status (<70), size of the effusion in chest radiographs (massive effusion), pleural fluid pH (<7.20), presence of concomitant alterations in chest radiographs, and pleural lactic acid dehydrogenase levels (>600 U/l) showed a significant association with the probability of failure. Patients with these features, along with those having non-chemosensitive tumours (in particular, non-small cell lung cancer), had a significantly worse actuarial survival. This study confirms that some pretreatment clinical data and pleural fluid parameters can predict both the outcome of pleurodesis and the survival of patients with malignant pleural effusion.
Related Articles:
References
- Rodríguez Panadero F, Borderas Naranjo F, López Mejías J: Pleural metastatic tumors and effusions. Frequency and pathogenic mechanism in a post-mortem series. Eur Respir J 1989;2:366–369.
- Good JT Jr, Taryle DA, Sahn SA: The pathogenesis of low glucose, low pH malignant effusions. Am Rev Respir Dis 1985;131:737–741.
- Rodríguez Panadero F, López Mejías J: Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989;139:663–667.
- Martínez-Moragón E, Aparicio J, Sanchis J, Fullana J, Sanchis F, Montalar J, Marco V: Pleurodesis con tetraciclinas en el tratamiento del derrame pleural maligno. Estudio retrospectivo de 91 casos. Med Clin (Barc) 1993;101:201–204.
- Sahn SA, Good JT Jr: Pleural fluid pH in malignant effusions: Diagnostic, prognostic, and therapeutic implications. Ann Intern Med 1988;108:345–349.
- Sánchez Armengol A, Rodríguez Panadero F: Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases. Chest 1993;104:1482–1485.
- Sahn SA: Pleural effusion in lung cancer. Clin Chest Med 1993;14:189–201.
- Paladine W, Cunningham TJ, Sponzo R, Donavan M, Olson K, Horton J: Intracavitary bleomycin in the management of malignant effusions. Cancer 1976;38:1903–1908.
- Chernow B, Sahn SA: Carcinomatous involvement of the pleura: An analysis of 96 patients. Am J Med 1977;63:695–702.
- Sahn SA: The pleura. State of the art. Am Rev Respir Dis 1988;138:184–234.
- Fentiman IS, Millis R, Sexton S, Hayward JL: Pleural effusion in breast cancer: A review of 105 cases. Cancer 1981;47:2087–2092.
- Villanueva AG, Gray Jr AW, Shahian DM, Williamson WA, Beamis JF Jr: Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax 1994;49:23–25.
- Reid PT, Rudd RM: Management of malignant pleural effusion. Thorax 1993;48:779–780.
-
Martínez Moragón E, Aparicio J, Rogado MC, Sanchis J, Sanchis F, Gil-Suay V: Pleurodesis in malignant pleural effusions: A randomised study of tetracycline versus bleomycin. Eur Respir J, in press.
- Walker-Renard PB, Vaughan LM, Sahn SA: Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994;120:56–64.
- Rodríguez Panadero F, López Mejías J: Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies. Chest 1989;95:320–324.
- Light RW: Lactate dehydrogenase isoenzymes in pleural effusions. Am Rev Respir Dis 1973;108:660–664.
-
Light RW: Clinical manifestations and useful tests; in Light RW (ed): Pleural Diseases, ed 2. Philadelphia, Lea & Febiger, 1990, pp 39–73.
-
American College of Chest Physicians. Current issues in pleurodesis. Pulmon Perspect 1991;8:9–10.
- Falkson G, Gelman RS, Pretorius FJ: Age as prognostic factor in recurrent breast cancer. J Clin Oncol 1986;4:663–671.
Article / Publication Details
Published online: April 03, 1998
Issue release date: March – April
Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 4
ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)
For additional information: https://www.karger.com/RES
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
